| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.4 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.4 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |